Drug-coated balloons versus drug-eluting stents for chronic total occlusion of coronary arteries

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter randomized trial in China comparing a DCB-based strategy (DCB alone or DCB with provisional DES) to standard DES-only treatment after successful recanalization of de novo CTO lesions. The primary imaging endpoint is in-segment late lumen loss at 9 months, with secondary endpoints including target lesion failure, cardiac death, myocardial infarction, and repeat revascularization. Eligible patients must have angiographically confirmed CTO with successful guidewire crossing, adequate vessel preparation, no flow-limiting dissection, and a reference vessel diameter of 2.25–4.0 mm. Patients will be enrolled at several tertiary hospitals and followed long-term to compare safety and clinical outcomes between the two strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient voluntarily participates in the study and has provided written informed consent.
* Presence of clinical indication for Percutaneous Coronary Intervention (PCI) of the Chronic Total Occlusion (CTO) (e.g., symptoms of angina pectoris or evidence of myocardial ischemia).
* Target lesion is located in a de novo coronary artery.
* Angiographically confirmed CTO (TIMI grade 0 flow), with evidence supporting an occlusion duration of ≥ 3 months.
* Successful guidewire crossing of the target CTO lesion has been achieved during the index procedure.
* After adequate vessel preparation: Distal TIMI grade 3 flow has been restored; Target lesion residual diameter stenosis is \< 50% (e.g., by visual estimate or QCA as per protocol); Absence of flow-limiting dissection or other complications requiring immediate stent implantation.
* Target vessel Reference Vessel Diameter (RVD) is between 2.25 mm and 4.0 mm (inclusive, assessed by visual estimate or QCA/IVUS as per protocol).
* In the judgment of the interventional operator, the lesion is deemed suitable for treatment with both a Drug-Coated Balloon (DCB)-based strategy and a Drug-Eluting Stent (DES)-only strategy.
* Patient is able and willing to comply with the study protocol requirements, including the specified follow-up schedule.
* Female patients of childbearing potential must have a negative pregnancy test prior to enrollment and agree to use an effective method of contraception throughout the study period.

Exclusion Criteria:

* Target CTO lesion is the culprit vessel responsible for the presenting Acute Myocardial Infarction (AMI).
* Patient is in cardiogenic shock.
* Presence of severe heart failure (New York Heart Association \[NYHA\] Class IV) or Left Ventricular Ejection Fraction (LVEF) \< 30%.
* History of stroke or Transient Ischemic Attack (TIA) within the previous 3 months.
* Known high risk of bleeding or contraindication to Dual Antiplatelet Therapy (DAPT).
* Presence of severe hepatic impairment and/or severe renal impairment (e.g., estimated Glomerular Filtration Rate \[eGFR\] \< 30 ml/min/1.73m² or requirement for chronic dialysis).
* Known hypersensitivity or contraindication to required study medications (e.g., antiplatelet agents, contrast media), DCB/DES drug coatings, or device materials (e.g., stent alloys, polymers).
* Target lesion located in an unprotected left main coronary artery, a saphenous vein graft, or an arterial graft.
* Presence of severe lesion calcification that prevents adequate vessel expansion despite attempted lesion preparation techniques (e.g., rotational atherectomy, intravascular lithotripsy).
* Target lesion is a CTO within a previously stented segment (In-Stent Restenosis \[ISR\] or In-Stent Thrombosis \[IST\]).
* Failed attempt at CTO recanalization during the index procedure (i.e., failure to cross the lesion with a guidewire or failure to restore TIMI grade 3 flow).
* Occurrence of a complication after vessel preparation that necessitates immediate stent implantation (e.g., flow-limiting dissection, perforation requiring a covered stent).
* Concurrent enrollment in another interventional clinical trial that may interfere with the study endpoints or assessments.
* Female patient is pregnant or breastfeeding.
* Patient judged by the investigator to be unsuitable for the study for any reason, including anticipated poor compliance with the protocol.

Where it's running

• Anyang District Hospital
  Anyang, Henan, China Recruiting
• The second people's Hospital of Jiyuan
  Jiyuan, Henan, China Recruiting
• Huaihe Hospital of Henan University
  Kaifeng, Henan, China Recruiting
• Kaifeng Central Hospital
  Kaifeng, Henan, China Recruiting
• The First Affiliated Hospital of Henan University of Science and Technology
  Luoyang, Henan, China Recruiting
• The Second People's Hospital of Pingdingshan
  Pingdingshan, Henan, China Recruiting

Study contacts

• Study coordinator: Liang Pan, Doctor
• Email: huzhoupanliang@163.com
• Phone: +86-15003851743

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TAVI and PCI vs SAVR and CABG in low- and intermediate-risk patients with severe aortic stenosis and CAD

  This observational study compares TAVI plus PCI to SAVR plus CABG for patients who have both severe aortic stenosis and coronary artery disease.

  Recruiting Alexandria University · Alexandria, Alexandira · NCT07926022

• Predicting Heart Muscle Recovery After CTO Revascularization

  This study looks at whether blood tests and stress echo measurements can predict which patients with CTO will regain heart muscle function after a revascularization procedure.

  Recruiting Assiut University · Asyut, Assuit · NCT07879573

• Resveratrol and Estrogen Receptors in Postmenopausal Women with CAD

  This study tests whether taking resveratrol is safe and can change estrogen-related markers in postmenopausal women with coronary artery disease.

  Recruiting InCor Heart Institute · São Paulo, São Paulo · NCT07865377

• Predicting Plaque Growth Using Blood Flow Stress Markers

  This study tests whether combining blood flow patterns in the heart arteries with how blood-flow–sensitive cells respond can help predict which plaques will grow in people with coronary artery disease.

  Recruiting Queen Mary University of London · London · NCT07864051

• Identifying Coronary Plaque Traits with Photon-counting CT and Multimodality Imaging

  This study tests whether advanced imaging can better identify risky artery plaques in people with stable angina.

  Recruiting Queen Mary University of London · London · NCT07864025

• Health for Hungary: Long-term blood and health data collection to study aging and disease onset

  This study tests whether routine blood tests plus advanced molecular analyses can help detect the early stages of non-communicable diseases in adults over 40.

  Recruiting at 21 sites Center for Molecular Fingerprinting Research Nonprofit LLC · Balatonfüred and 32 other locations · NCT07743021

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.